- Home
- FINW vs IPHA Comparison
FINW vs IPHA Comparison
Compare FINW & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- IPHA
- Stock Information
- Founded
- FINW 1999
- IPHA 1999
- Country
- FINW United States
- IPHA France
- Employees
- FINW N/A
- IPHA 179
- Industry
- FINW Commercial Banks
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- IPHA Health Care
- Exchange
- FINW Nasdaq
- IPHA Nasdaq
- Market Cap
- FINW 188.0M
- IPHA 171.6M
- IPO Year
- FINW 2021
- IPHA 2019
- Fundamental
- Price
- FINW $14.42
- IPHA $2.24
- Analyst Decision
- FINW Buy
- IPHA Strong Buy
- Analyst Count
- FINW 1
- IPHA 1
- Target Price
- FINW $17.00
- IPHA $11.50
- AVG Volume (30 Days)
- FINW 10.1K
- IPHA 6.0K
- Earning Date
- FINW 10-24-2024
- IPHA 09-12-2024
- Dividend Yield
- FINW N/A
- IPHA N/A
- EPS Growth
- FINW N/A
- IPHA N/A
- EPS
- FINW 1.18
- IPHA N/A
- Revenue
- FINW $67,148,000.00
- IPHA $36,202,722.00
- Revenue This Year
- FINW N/A
- IPHA N/A
- Revenue Next Year
- FINW $13.35
- IPHA $105.84
- P/E Ratio
- FINW $12.31
- IPHA N/A
- Revenue Growth
- FINW 3.24
- IPHA N/A
- 52 Week Low
- FINW $8.31
- IPHA $1.81
- 52 Week High
- FINW $14.98
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- FINW 76.46
- IPHA 47.10
- Support Level
- FINW $13.64
- IPHA $2.22
- Resistance Level
- FINW $13.25
- IPHA $2.35
- Average True Range (ATR)
- FINW 0.48
- IPHA 0.13
- MACD
- FINW 0.10
- IPHA -0.01
- Stochastic Oscillator
- FINW 93.15
- IPHA 32.35
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank also has established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.